{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:18:16Z","timestamp":1781713096958,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hoc.2025.12.004","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T20:34:29Z","timestamp":1767386069000},"page":"275-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Selection of a Salvage Regimen for Relapsed or Refractory Classic Hodgkin Lymphoma in the Era of Novel Therapies"],"prefix":"10.1016","volume":"40","author":[{"given":"Annie","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.hoc.2025.12.004_bib1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.004_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with Brentuximab vedotin in stage III or IV hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"10450","key":"10.1016\/j.hoc.2025.12.004_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.004_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.004_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.004_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2025.12.004_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022018827","article-title":"Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents","author":"Spinner","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.004_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2023-179573","article-title":"PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed\/refractory classic hodgkin lymphoma: results from a multicenter cohort","volume":"142","author":"Desai","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.004_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory hodgkin lymphoma","volume":"9","author":"Mei","year":"2025","journal-title":"HemaSphere"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.004_bib10","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.004_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic hodgkin lymphoma","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hoc.2025.12.004_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.HS9.0000890964.54059.2c","article-title":"T099: high efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma","volume":"6","author":"Moskowitz","year":"2022","journal-title":"HemaSphere"},{"issue":"28","key":"10.1016\/j.hoc.2025.12.004_bib13","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.004_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.004_bib15","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.004_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.004_bib17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2025.12.004_bib18","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/annonc\/mdg703","article-title":"Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-hodgkin\u2019s lymphoma and Hodgkin\u2019s disease","volume":"14","author":"Hertzberg","year":"2003","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.004_bib19","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1182\/blood-2024-200719","article-title":"Pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin (P-GVD) for classical Hodgkin Lymphoma (CHL) in the real-world setting","volume":"144","author":"Baek","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.004_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-Year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.004_bib21","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.004_bib22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study","volume":"106","author":"Jos\u00e9 Kersten","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.004_bib23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.004_bib24","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2024-211527","volume":"144","author":"Sureda Balar\u00ed","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.004_bib25","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/bloodadvances.2023012145","article-title":"Brentuximab vedotin and chemotherapy in relapsed\/refractory Hodgkin lymphoma: a propensity score-matched analysis","volume":"8","author":"Driessen","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.004_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.004_bib27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","article-title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"29","author":"Herrera","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.004_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16499","article-title":"Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma","volume":"189","author":"LaCasce","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.004_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.004_bib30","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin\u2019s lymphoma (AHOD1221): a Children\u2019s oncology group, multicentre single-arm, phase 1\u20132 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2025.12.004_bib31","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1080\/10428194.2022.2107204","article-title":"Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory\/relapsed Hodgkin lymphoma: a lymphoma study association phase I\/II study","volume":"63","author":"Stamatoullas","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.hoc.2025.12.004_bib32","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended Follow-Up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.004_bib33","doi-asserted-by":"crossref","first-page":"e993","DOI":"10.1634\/theoncologist.2020-0040","article-title":"Impact of treatment beyond progression with immune checkpoint blockade in Hodgkin Lymphoma","volume":"25","author":"Merryman","year":"2020","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.004_bib34","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory hodgkin lymphoma: a series from lysa centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.004_bib35","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","article-title":"Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.004_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.004_bib37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-021-04429-8","article-title":"Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma","volume":"100","author":"Fedorova","year":"2021","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2025.12.004_bib38","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2025.12.004_bib39","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.004_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/10428194.2019.1654100","article-title":"Retreatment with brentuximab vedotin in patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study","volume":"61","author":"Fukuhara","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.004_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-025-01257-1","article-title":"Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers","volume":"15","author":"Voorhees","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.004_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.004_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/annonc\/mdt349","article-title":"Immunological off-target effects of standard treatments in gastrointestinal cancers","volume":"25","author":"Duffy","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.004_bib44","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3324\/haematol.2022.282266","article-title":"Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial","volume":"108","author":"Ding","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.004_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19178","article-title":"Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma","volume":"204","author":"Stuver","year":"2024","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.hoc.2025.12.004_bib46","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2023020485","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.004_bib47","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood-2023-190753","article-title":"The combination of Nivolumab and CC-486 is active in hodgkin lymphoma refractory to PD-1 blockade","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2025.12.004_bib48","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"},{"issue":"9980","key":"10.1016\/j.hoc.2025.12.004_bib49","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.004_bib50","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.004_bib51","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3324\/haematol.2023.282780","article-title":"Effect of cumulative dose of brentuximab vedotin maintenance in relapsed\/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes","volume":"108","author":"Wagner","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.004_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.004_bib53","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood-2021-148139","article-title":"A phase II single arm Study of Nivolumab as maintenance therapy after autologous stem cell transplantation in patients with hodgkin lymphoma at risk of relapse or progression","volume":"138","author":"Bachier","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.004_bib54","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.004_bib55","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2023-182318","article-title":"Efficacy of Brentuximab vedotin maintenance therapy following autologous stem cell transplantation in patients with Relapsed\/refractory classical hodgkin lymphoma with and without pre-transplant exposure to novel agents","volume":"142","author":"Falade","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.004_bib56","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-022-05011-6","article-title":"Impact of pre- and\/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma","volume":"102","author":"Mart\u00ednez","year":"2023","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.004_bib57","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41409-025-02557-7","article-title":"Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: a systematic review and meta-analysis","volume":"60","author":"Sureda","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.004_bib58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamaoncol.2024.5627","article-title":"Transplant-free approach in relapsed hodgkin lymphoma in children, adolescents, and young adults","volume":"11","author":"Daw","year":"2025","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.004_bib59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2024-202537","article-title":"Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.004_bib60","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41375-021-01442-8","article-title":"Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis","volume":"36","author":"Br\u00f6ckelmann","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.004_bib61","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.004_bib62","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2021004970","article-title":"Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma","volume":"6","author":"Zinzani","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.004_bib63","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.ijrobp.2005.05.006","article-title":"Long-term follow-up of salvage radiotherapy in Hodgkin\u2019s lymphoma after chemotherapy failure","volume":"63","author":"Campbell","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.004_bib64","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.004_bib65","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.004_bib66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12916-024-03329-8","article-title":"Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial","volume":"22","author":"Liu","year":"2024","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.004_bib67","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.004_bib68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2023-184531","article-title":"Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and Brentuximab vedotin in patients with relapsed\/refractory classic hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412)","volume":"142","author":"Diefenbach","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.004_bib69","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-019-0265-x","article-title":"First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the fondazione italiana linfomi","volume":"9","author":"Broccoli","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.004_bib70","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:25:12Z","timestamp":1773955512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0889858825001455"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection of a Salvage Regimen for Relapsed or Refractory Classic Hodgkin Lymphoma in the Era of Novel Therapies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}